This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

Syros Announces Update on Selective CDK7 Inhibitor Portfolio Prioritizing Development of SY-5609, Its Oral CDK7 Inhibitor, and Discontinuing Further Development of SY-1365, Its Intravenous CDK7 ...

Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University.

For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge. New CU Boulder research, published in the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been ...

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of ...

Immunohistochemical staining Hematoxylin-Eosin, highlights a malignant proliferate tumor (adnocarcinoma), adipose tissue (abdominal fat) infiltrated by a malignant lesion of pancreatic origin. Nerve ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent anti-tumor ...

Stephen has degrees in science (Physics major) and arts (English Literature and the History and Philosophy of Science), as well as a Graduate Diploma in Science Communication. Stephen has degrees in ...